Changing the Subject: The “All-Cancer Trial”
Executive Summary
Rather than try to “win” the drug pricing debate, the biopharma sector may be better served by coming up with new ideas to change the subject. One idea: a nationwide clinical trial open to every patient with a cancer diagnosis.